Here is my latest effort! I hope everything is correct — it’s a table that is meant to include all the clinical trials and high-quality retrospective and observational studies discussed on the site.
Each entry includes a link to the clinical trial (when available in the original article) as well as a link to the full article on the website.
The table can be sorted in ascending or descending order by any column.

RPFS = radiographic progression-free survival; if an * is present, the result refers to some form of stratification (for example, the presence or absence of a genetic mutation, metastatic burden, etc.).
OS = overall survival, with the same note regarding the presence of an *.
PSA50 = percentage of patients who achieved at least a 50% decline in PSA. Same meaning of the * next to the number.

Please contact me if you encounter any issues while using or viewing the table.

NCT ID	Stage	Trial / Drug	Phase	rPFS (months)	OS (months)	PSA 50 (%)
NCT07359066	mCRPC	SPR1020 / PARP1 inhibitor Next-generation selective PARP1 inhibitor designed to reduce blood count toxicity compared to olaparib. Targets HRR-deficient tumors (BRCA-mutated) and penetrates the brain.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC	GTB-5550 / B7-H3 TriKE Immunotherapy targeting B7-H3, highly expressed in advanced PCa. Uses TriKE technology to activate Natural Killer (NK) cells and IL-15 to sustain immune assault under hypoxia.	1	n.a.	n.a.	n.a.
NCT06784193	mCRPC	UPDATE: OP-3136 / KAT6A/B inhibitor Epigenetic regulator targeting KAT6A/B. Specifically for mCRPC patients who failed standard therapies. Shows synergy when combined with docetaxel.	1	n.a.	n.a.	n.a.
n.a.	mHSPC / mCRPC	Alliance A222001 / Oxybutynin Repurposed bladder drug to manage ADT-induced hot flashes. High dose (5mg) achieved a 68% reduction in symptoms compared to placebo.	2	n.a.	n.a.	n.a.
NCT06616155	mCRPC	JASPER / Ruxolitinib + Enzalutamide Targets the JAK/STAT inflammatory signaling axis to block lineage plasticity (AR-negative and neuroendocrine-like states) in AR-insensitive tumors.	1/2	n.a.	n.a.	n.a.
NCT07150715	mHSPC	ANDROMEDA / 225Ac-PSMA-617 vs 177Lu-PSMA-617 Head-to-head trial of Alpha vs Beta PSMA therapy for oligorecurrent disease. Investigates if high-energy Alpha emission better eradicates microscopic metastases.	2	17.6*	n.a.	n.a.
NCT06966024	mCRPC	DCC-2812 / GCN2 kinase activator Turns on the integrated stress response (ISR) via GCN2 kinase to overload cancer cells and trigger apoptosis. Useful for hormone-resistant tumors.	1	n.a.	n.a.	n.a.
NCT04633252	mCRPC	PDS01ADC (M9241) + Docetaxel Immunocytokine IL-12 targeting necrotic tumor regions. Designed to boost the efficacy of docetaxel in heavily pretreated mCRPC populations.	1/2	9.6	n.a.	37.5
NCT07365995	mCRPC	BNT324 (DB-1311) vs Docetaxel First-in-class B7-H3-targeting ADC. Data shows strong response rates even in patients who failed PARP inhibitors and Lu-177 PSMA therapy.	3	8.5*	n.a.	n.a.
n.a.	mCRPC / NEPC	SKL35501 / NTSR1-targeted Ac-225 Targeting Neurotensin Receptor 1 (NTSR1), which is enriched in PSMA-negative advanced disease and Neuroendocrine Prostate Cancer (NEPC).	1	n.a.	n.a.	n.a.
NCT07354594	mCRPC	ARREST / 177Lu-PSMA + Radiotherapy boost Uses targeted external beam radiation to eliminate ‘cold spots’ missed by systemic Lu-177. Radiotherapy also supercharges PSMA expression on cancer cells.	2	n.a.	n.a.	n.a.
NCT06136650	mCRPC	MK-5684-004 / Opevesostat CYP11A1 inhibitor blocking the first step of hormone production. Specifically targeted at patients with Androgen Receptor Ligand-Binding Domain (AR-LBD) mutations.	3	5*	n.a.	73.7*
NCT07344311	mCRPC	A-CAR032 / STEAP2 CAR-T Armored CAR-T cell therapy targeting STEAP2. Includes a shield to block immunosuppressive TGF-beta signals from the tumor microenvironment.	1	n.a.	n.a.	n.a.
NCT07341737	mCRPC	SL-28 / Leukocyte-Tells Off-the-shelf donor cell therapy. A striking case study showed PSA reduction from 10.4 to 0.1 without requiring ADT-level testosterone suppression.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC	UPDATE: SECuRE / 67Cu-SAR-bisPSMA Copper-67 PSMA radioligand therapy. Demonstrated a 66.7% PSA50 response in heavily pretreated mCRPC patients with bone metastases.	2	n.a.	n.a.	66.7
NCT06236139	mCRPC	STEAP1 CAR-T + Enzalutamide Combines CAR-T cells targeting STEAP1 with Enzalutamide. Preclinical data showed complete disappearance of measurable disease in mouse models.	1	n.a.	n.a.	n.a.
NCT07336446	mCRPC	ANDROMEDA / AZD9750 (AR PROTAC) Proteolysis-targeting chimera (PROTAC) that degrades the AR protein completely. Combined with Saruparib to exploit DNA repair vulnerabilities (BRCA/ATM).	1/2	n.a.	n.a.	n.a.
NCT07332455	mCRPC	GSK5471713 / AR Degrader Small-molecule AR degrader aimed at overcoming resistance mechanisms like AR overexpression and splice variants by physically destroying the receptor.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC (HRD+)	BrUOG360 / Copanlisib + Rucaparib Targets concurrent HRD and PI3K pathway alterations. Investigates if PI3K inhibition can re-sensitize PARP-resistant tumors (BRCA1/2, PTEN loss).	1b/2	n.a.	n.a.	23*
n.a.	mCRPC	UPDATE: PT-112 / Pyrophosphate Platinum Platinum-based agent with bone-seeking properties (osteotropism). Effective in neuroendocrine-like, AR-non-responsive end-stage disease.	3	5*	n.a.	n.a.
NCT07311694	mCRPC	HRS-4357 / PSMA Radioligand Chinese randomized Phase 3 trial comparing new radioligand to NHA switching. Specifically for patients progresssed on exactly one prior ARPI.	3	n.a.	n.a.	n.a.
NCT07310433	mCRPC	Dapagliflozin + NHA SGLT2 inhibitor (diabetes drug) used to block glucose uptake. Exploits the metabolic ‘Warburg effect’ vulnerability in castration-resistant cells.	2	n.a.	n.a.	n.a.
NCT07298239	mCRPC	Allogeneic CAR-NK / PSMA target Off-the-shelf Natural Killer cells modified to target PSMA. Potentially faster and safer than patient-specific CAR-T therapies.	1	n.a.	n.a.	n.a.
NCT04887935	nmHSPC	Dapagliflozin Neoadjuvant Pilot trial in high-risk localized PCa (before surgery). Measures impact on metabolic biomarkers (glucose, insulin) and tumor shrinkage.	1	n.a.	n.a.	n.a.
NCT07287150	mCRPC	InavoPC / Inavolisib Ultra-selective PI3Kα inhibitor for patients with PTEN loss (40-60% of mCRPC). Blocks PI3K-AKT signals that drive resistance to hormonal therapy.	3	n.a.	n.a.	n.a.
NCT07288359	mCRPC	GVV858 / CDK2 inhibitor Targeting the cell cycle in CCNE1-amplified tumors. Aims to block the ‘escape route’ tumors use when ADT fails to stop division.	1/2	n.a.	n.a.	n.a.
NCT07285694	mCRPC	UPDATE: AB-3028 / Logic-gated CAR-T Programmable CAR-T cells requiring dual antigen recognition (PSMA + second priming antigen) to activate, reducing damage to healthy tissues.	1/2	n.a.	n.a.	n.a.
NCT06136884	mCRPC	UPDATE: AO-252 / TACC3 inhibitor Brain-penetrating oral inhibitor of TACC3. Disrupts mitosis to cause tumor shrinkage (22% seen in early data). Active in p53-mutated tumors.	1	n.a.	n.a.	n.a.
NCT07277270	mCRPC	GSK5764227 / B7-H3 ADC + Enzalutamide Combines AR blockade with cytotoxic delivery to B7-H3 positive cells. Aims to overcome resistance where B7-H3 correlates with poor prognosis.	1/2	n.a.	n.a.	n.a.
NCT07192120	mCRPC	MHB048C / PSMA-Targeted ADC Antibody-drug conjugate delivering Topoisomerase I inhibitor directly to PSMA cells. Features a bystander effect for antigen-heterogeneous lesions.	1/2	n.a.	n.a.	n.a.
NCT07268794	mHSPC	CONVERT-HB1 / Local + Systemic Therapy Tests local treatment of primary tumor in high-volume patients who respond deeply to systemic therapy (induction ADT/ARPI/Docetaxel).	2	n.a.	n.a.	n.a.
NCT04876651	mCRPC	ProstACT Global / TLX591 Beta-emitting PSMA antibody (rosopatamab). Antibody size minimizes dry mouth side effects compared to small-molecule radioligands (Pluvicto).	3	n.a.	n.a.	n.a.
NCT07258407	mCRPC	TD001 / PSMA ADC PSMA-directed ADC using Exatecan (Top1 inhibitor). Potentially effective in tumors with lower or heterogeneous PSMA expression.	1/2	n.a.	n.a.	n.a.
NCT05320406	mHSPC	REVELUTION / Relugolix vs Leuprolide Prospective study showing relugolix (antagonist) causes significantly less coronary plaque progression than leuprolide (agonist) over 12 months.	2	n.a.	n.a.	n.a.
n.a.	mCRPC	ITC-6146RO / B7-H3 ADC Highly stable ADC targeting B7-H3. Uses OHPAS linker and duocarmycin payload to minimize premature toxic release in blood.	1	n.a.	n.a.	n.a.
NCT04471727	mCRPC / NEPC	MK-6070 / DLL3 Trispecific T-Cell Engager Targets DLL3 on aggressive neuroendocrine tumors. Trispecific design binds DLL3, CD3, and albumin to extend half-life and trigger precise T-cell killing.	1/2	n.a.	n.a.	n.a.
NCT07252414	mCRPC	UPDATE: GenSci143 / Bispecific ADC (B7-H3 + PSMA) Dual-target antibody-drug conjugate targeting B7-H3 and PSMA simultaneously to overcome tumor heterogeneity and resistance in advanced prostate cancer.	1	n.a.	n.a.	n.a.
NCT07250542	mCRPC	Fasudil Hydrochloride + PD-1 Checkpoint Blockade ROCK inhibitor (Fasudil) used to normalize tumor vasculature and reduce hypoxia, potentially turning ‘cold’ prostate tumors into ‘hot’ ones responsive to PD-1 immunotherapy.	2	n.a.	n.a.	n.a.
NCT07244341	mCRPC	Valemetostat + Darolutamide Dual EZH1/2 inhibitor combined with darolutamide. Targets epigenetic drivers (PRC2 complex) to overcome lineage plasticity and neuroendocrine differentiation.	1/2	n.a.	n.a.	n.a.
NCT07244393	mCRPC	KEYNOTE-G28 / 177Lu-DGUL + Pembrolizumab Combination of PSMA radioligand and PD-1 inhibitor. 177Lu-DGUL induces immunogenic cell death, potentially priming the tumor for pembrolizumab’s immune boost.	1	n.a.	n.a.	81*
n.a.	mCRPC	GTB-5550 / Tri-specific NK Cell Engager Engages B7-H3 and CD16 while delivering IL-15 directly to Natural Killer cells. Designed to maintain activity in immunosuppressive tumor niches.	1	n.a.	n.a.	n.a.
NCT07241416	mHSPC	Rezvilutamide vs Enzalutamide Head-to-head Phase 3 trial comparing two next-gen AR antagonists. Rezvilutamide is designed to have lower brain penetration, potentially reducing fatigue and seizures.	3	n.a.	n.a.	n.a.
NCT07230106	mCRPC	SHR3680 + HS-20093 + SHR2554 (Triplet Therapy) Combines AR antagonist, B7-H3 ADC, and EZH2 inhibitor. Targets androgen signaling, cytotoxic delivery, and epigenetic regulation simultaneously.	2	n.a.	n.a.	n.a.
n.a.	mCRPC / nmHSPC	RAD 402 / Terbium-161 KLK3 Antibody Targets KLK3 (PSA gene). Uses Terbium-161, which emits both beta and Auger electrons for short-range lethal energy against micrometastases.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	EVOLUTION / 177Lu-PSMA + Ipilimumab/Nivolumab Tests if dual checkpoint blockade improves Pluvicto outcomes. 33% of patients were progression-free at 12 months in the combination arm vs 17% in monotherapy.	2	12*	n.a.	n.a.
NCT07226986	mCRPC	AMO959 + Pluvicto + ARPI AMPK activator combined with Pluvicto and standard ARPI. Aims to disrupt cancer cell metabolism while delivering targeted radiation.	1b/2	n.a.	n.a.	n.a.
NCT07226713	mCRPC (Stat5+)	POSTPONE / Pacritinib JAK2/IRAK1 inhibitor for patients with high nuclear Stat5 activation (>5% of cells). Targets a key resistance loop driven by AR signaling inhibitors.	2	n.a.	n.a.	n.a.
NCT07225946	mCRPC	KLK2-PASenger / Pasritamig + Docetaxel Bispecific T-cell engager targeting KLK2 combined with chemotherapy. Uses intermittent dosing to preserve T-cell fitness and avoid exhaustion.	3	n.a.	n.a.	40*
n.a.	mCRPC	GenSci143 / Bispecific ADC (B7-H3 + PSMA) Designed to overcome single-antigen loss or heterogeneity. Combines two validated prostate targets with a Topoisomerase I inhibitor payload.	1	n.a.	n.a.	n.a.
NCT07224009	mHSPC / mCRPC	Low-Dose Naltrexone for ADT Fatigue Investigates if 3mg naltrexone reduces ADT-induced fatigue by modulating mitochondrial bioenergetics and reducing pro-inflammatory cytokines like IL-6.	2	n.a.	n.a.	n.a.
NCT07219147	mCRPC	Pluvicto + Sipuleucel-T Sequential strategy using radioligand therapy to cause antigen release, followed by Sipuleucel-T to boost the specific immune response against PAP.	1	n.a.	n.a.	n.a.
NCT06800313	mCRPC	UPDATE 2: HLD-0915 / RIPTAC Bifunctional molecule that binds AR and BRD4 to kill cancer cells. Preliminary data: 59% PSA50 response and 32% PSA90 response in heavily pretreated patients.	1/2	n.a.	n.a.	59
n.a.	nmHSPC	EMBARK / Enzalutamide + ADT Final OS data for high-risk biochemical recurrence. Combo reduces death risk by 40% over 8 years compared to hormone therapy alone.	3	n.a.	96*	n.a.
NCT05534646	mCRPC	UPDATE: ENV-105 (Carutoximab) + Apalutamide CD105 antagonist targeting the microenvironment. Interim data: median PFS of 13 months, significantly better than standard 2nd/3rd line hormone therapies.	2	13	n.a.	77.7*
NCT06190899	mCRPC	Gedatolisib + Darolutamide Dual PI3K/mTOR inhibitor + AR blocker. Early data shows 6-month rPFS rate of 66% in patients who failed prior AR pathway inhibitors.	1/2	6.5*	n.a.	n.a.
n.a.	mCRPC	ADVC001 / Lead-212 Alpha Therapy PSMA-targeted Lead-212 isotope. 80% of patients achieved PSA50 response. Includes complete radiographic responses within weeks of starting.	1b	n.a.	n.a.	80
n.a.	nmHSPC	PRESTO / Apalutamide Intensification For biochemical relapse with rapid PSA doubling time. Adding apalutamide to ADT improved PSA-PFS from 20 to 25 months without delaying testosterone recovery.	3	25*	n.a.	n.a.
n.a.	nmHSPC (Local/Advanced)	ENZARAD / Enzalutamide Intensification Subgroup analysis shows enzalutamide + ADT + Radiation significantly improves MFS (87% vs 77%) only in node-positive (N1) disease.	3	n.a.	83*	n.a.
n.a.	mHSPC	PSMAddition / Pluvicto + ADT + ARPI Pluvicto moved to frontline hormone-sensitive setting. Reduced progression risk by 28%. 57.1% achieved complete radiographic response.	3	n.a.	n.a.	n.a.
n.a.	mCRPC	AlphaBet / 177Lu-PSMA + 223Ra Dual radionuclide therapy targeting bone (Radium-223) and soft tissue (Lutetium-177). Over 50% PSA50 response rate in bone-dominant disease.	1/2	n.a.	n.a.	50
n.a.	mHSPC	ARASAFE / Alternative Docetaxel Schedule Compares 50mg bi-weekly vs standard 75mg tri-weekly Docetaxel. Alternative schedule reduced severe neutropenia/death risk (24% vs 64%) with same efficacy.	3	43.7*	n.a.	n.a.
n.a.	mCSPC / mCRPC	PETRANHA / Saruparib (PARP1) Next-gen PARP1 inhibitor. 88.5% ORR in mCSPC. Benefits seen in both HRR-mutated and wild-type patients, with improved hematologic safety.	1/2	n.a.	n.a.	83*
n.a.	nmHSPC	Co-PSMA / 64Cu-SAR-bisPSMA Copper-based PET tracer identified twice as many lesions as 68Ga standard due to longer half-life (12.7h) allowing for next-day imaging.	2	n.a.	n.a.	n.a.
NCT07216248	mHSPC	PSA-Triggered Intermittent Therapy / Relugolix Tests intermittent ADT using Relugolix + ARPI. Therapy is paused when PSA < 0.2, aiming to reduce side effects like metabolic and sexual dysfunction.	2	n.a.	n.a.	n.a.
NCT07213674	mCRPC	Xaluritamig (AMG 509) + Abiraterone Large Phase 3 trial for chemo-naive patients. Combines STEAP1-targeting bispecific engager with hormonal suppression (Abiraterone).	3	n.a.	n.a.	n.a.
NCT07214961	mCRPC	ARTISAN / AB001 (Lead-212 Alpha Radioligand) Lead-212 isotope targeting PSMA. Fractionated dosing aimed at high localized energy delivery with reduced systemic side effects.	1	n.a.	n.a.	n.a.
NCT07206056	mCRPC	Tulmimetostat + JSB462 (Luxdegalutamide) Combines EZH1/2 inhibitor with AR PROTAC. Targets both the epigenetic silencing and the physical degradation of mutated androgen receptors.	1/2	n.a.	n.a.	43*
n.a.	mCRPC	UPDATE: VIR-5500 / Dual-Masked T-cell engager Utilizes XTEN masking to activate T-cells only in the tumor environment. PSA50 response achieved in 58% of patients, even those with high burden.	1	n.a.	n.a.	58
n.a.	mCSPC (HRR+)	AMPLITUDE / Niraparib + Abiraterone Moves PARP inhibitors to first-line mCSPC for HRR-mutated patients. Reduced risk of progression or death by 48% in BRCA1/2 patients.	3	26*	n.a.	n.a.
n.a.	mCRPC	Cabazitaxel vs ARPI Switch Prospective Phase 2b for poor prognosis disease. Prior ARPI exposure predicted failure of ARPI switch, making Cabazitaxel a better choice in that setting.	2b	n.a.	30.9*	47.2*
n.a.	mHSPC (Oligorecurrent)	LUNAR / 177Lu-PNT2002 + SBRT Phase 2 trial for oligorecurrent PCa. Combining PSMA radioligand therapy with SBRT more than doubled rPFS (17.6 vs 7.4 months) and delayed ADT by a year.	2	17.6	n.a.	n.a.
n.a.	mHSPC	ASPIRE / Docetaxel + Apalutamide Large Phase 3 trial evaluating treatment intensification by adding docetaxel to apalutamide and ADT. Incorporates genetic profiling for TP53, PTEN, and RB1 mutations.	3	n.a.	n.a.	n.a.
n.a.	mCRPC	Phase 1 / 161Tb-PSMA First clinical results for Terbium-161 PSMA in patients who failed 177Lu-PSMA. Achieved 57% PSA50 response and objective imaging response in 57% of participants.	1	n.a.	n.a.	57
n.a.	mCRPC (Poly-metastatic)	Combination ARSI + Denosumab + Radiotherapy Multi-modal approach for patients with high-volume bone disease (≥4 lesions). 85% achieved ≥90% PSA reduction and 50% achieved undetectable PSA.	2	n.a.	n.a.	85
n.a.	nmHSPC	BALANCE / Apalutamide + Salvage Radiation Uses PAM50 genomic subtyping to identify Luminal B tumors. Subtype-specific benefit: 5-year MFS improved to 94.7% vs 81.8% in the control.	2	n.a.	n.a.	n.a.
NCT07192614	mCRPC	ACTIVATED-4-PC / AZD6621 T-cell engager targeting STEAP2. Preferentially activates CD8+ killer T-cells over CD4+ cells to maximize cancer kill and reduce inflammatory cytokine release.	1/2	n.a.	n.a.	n.a.
NCT07190300	mHSPC	TulmiSTAR-02 / Tulmimetostat + ARPI Combines EZH2 inhibitor with Darolutamide or Abiraterone. Targets epigenetic regulation to delay emergence of resistance in newly diagnosed metastatic disease.	1/2	n.a.	n.a.	n.a.
NCT07181161	mCRPC	AZD0516 / STEAP2 ADC Antibody-drug conjugate targeting STEAP1/2. Paired with brain-penetrant PARP1 inhibitor (AZD9574) to exploit DNA repair mechanisms via synthetic lethality.	1/2a	n.a.	n.a.	n.a.
NCT07179783	mCRPC / NEPC	Sacituzumab Tirumotecan + Tagitanlimab ADC targeting Trop-2 combined with PD-L1 inhibitor. Focuses on aggressive variant PCa and neuroendocrine subtypes where standard hormone therapy fails.	2	n.a.	n.a.	n.a.
NCT07181473	mCRPC	TJ101 / Bispecific ADC (EGFR + B7-H3) Dual-targeting ADC attacking EGFR and B7-H3 simultaneously. Designed for hormone-resistant cases where B7-H3 is abundant.	1	n.a.	n.a.	n.a.
n.a.	nmHSPC	OST-504 / Listeria-based Immunotherapy Uses a live attenuated Listeria vector to deliver 24 prostate-associated antigens. Aims to induce T-cell responses in biochemical recurrence patients.	1b	n.a.	n.a.	n.a.
NCT07164794	mCRPC / NEPC	Memantine / NMDA Receptor Antagonist Repurposed Alzheimer’s drug. Blocks NMDA receptors which fuel a ‘glutamatergic signaling autocrine loop’ driving aggressive neuroendocrine transformation.	2	n.a.	n.a.	n.a.
NCT07164443	mCRPC	KLK2-comPAS / Pasritamig Phase 3 randomized trial comparing KLK2-targeting bispecific T-cell engager vs placebo in late-line mCRPC. Preliminary data: 40% PSA50 response.	3	8*	n.a.	40
n.a.	mCRPC	AB001 / Lead-212 PSMA Alpha therapy Targets PSMA with short-lived isotope Lead-212. Preclinical data suggests stronger tumor control than Pluvicto (beta-emitter) when given in fractionated doses.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	UPDATE: 177Lu-DGUL South Korean PSMA radioligand. Achieved 35.9% ORR (RECIST) and 81% (PET). Significantly lower xerostomia (13.2% vs 38.8% for Pluvicto).	2	n.a.	n.a.	81*
n.a.	mCRPC	Low-Dose Abiraterone (250mg) + Food Brazil study showing 250mg dose with a low-fat meal is as effective as 1000mg fasted. PSA50 response rate was 68.3% in earlier stage patients.	2	7.9	20.6	68.3*
n.a.	mHSPC	ARCHES (5-Year Follow-up) / Enzalutamide Updated data: Enzalutamide + ADT boosted overall survival by 30%. Benefit particularly strong for high-volume disease (median OS 7 years vs 4 years).	3	n.a.	84*	n.a.
n.a.	mCRPC	ITC-6146RO / B7-H3 ADC ADC targeting B7-H3 with OHPAS linker and duocarmycin payload. Specifically designed to avoid off-target damage and liver toxicity.	1	n.a.	n.a.	n.a.
n.a.	mCRPC (MMR-deficient)	Anti-PD-L1 (Atezolizumab/Durvalumab) Specific for MMR-deficient/MSI-H prostate cancer (5% of cases). 60% achieved PSA50 reduction. Median OS reached 27 months in this subgroup.	n.a.	7.7	27	60
NCT07142551	mHSPC	SPIDERMAN / BAT + Darolutamide Bipolar Androgen Therapy (BAT) alternating high/low testosterone combined with darolutamide. Aims to extend hormone sensitivity and reduce side effects.	2	n.a.	n.a.	n.a.
NCT07140900	mHSPC	Xaluritamig (AMG 509) + ARPI STEAP1-targeted immunotherapy moved to frontline hormone-sensitive setting. Evaluates synergy with Abiraterone and Darolutamide.	1	n.a.	n.a.	n.a.
NCT05396833	mCRPC (ATM mutant)	Lartesertib + Tuvusertib Combines ATM and ATR inhibitors. Creates a ‘double hit’ on DNA repair systems, particularly effective in ATM-deficient tumors (20-30% of cases).	1	n.a.	n.a.	n.a.
NCT04543903	Localized / Metastatic	Alpha DaRT / Radium-224 seeds Implanted seeds coated with Radium-224. Emits alpha particles with extremely short range (mm) for ultra-precise destruction of tumors while sparing rectum/bladder.	Pilot	n.a.	n.a.	n.a.
NCT07114601	mCRPC	OMNIRAY / LY4257496 (GRPR Radioligand) Targets Gastrin-Releasing Peptide Receptor (GRPR). Potential option for PSMA-negative tumors or patients who previously failed Pluvicto.	1	n.a.	n.a.	n.a.
n.a.	n.a.	Fasting-Mimicking Diets (FMD) Compares high vs low protein plant-based fasting. Both induced autophagy and IGF-1 reduction (35%), but High Protein FMD better reduced visceral fat.	n.a.	n.a.	n.a.	n.a.
NCT06347705	mCRPC	2141-V11 / CD40 Agonist Enhanced CD40 agonist injected directly into tumors. Replaces tumor tissue with Tertiary Lymphoid Structures (TLS). Induced systemic responses in non-injected sites.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC	UPDATE: HLD-0915 / Fast Track RIPTAC molecule inducing proximity between AR and an effector protein. Granted FDA Fast Track for advanced cases with emerged resistance.	1/2	n.a.	n.a.	59
NCT06172283	mHSPC / nmHSPC	Intermittent Fasting Adjuvant Tests if alternate-day fasting increases enzalutamide efficacy. Preclinical models showed 85% reduction in lesions and decreased tumor protein synthesis.	1/2	n.a.	n.a.	n.a.
NCT07111507	NEPC	Tarlatamab / DLL3 bispecific engager Specifically for Neuroendocrine Prostate Cancer (NEPC). Targets DLL3 protein. Early results show higher objective response rates in DLL3-positive patients.	2	n.a.	n.a.	n.a.
NCT07104643	mCRPC	TYK-00540 + Enzalutamide Oral inhibitor targeting CDK2/4/6. Designed to overcome resistance to earlier CDK4/6 inhibitors by disrupting multiple cell cycle pathways.	1b/2	n.a.	n.a.	n.a.
NCT07104617	mCRPC	TY-302 + Abiraterone Combines a CDK4/6 inhibitor with Abiraterone. Aims to stop cancer cell proliferation while blocking androgen production simultaneously.	1b/2	n.a.	n.a.	n.a.
n.a.	mCRPC / NEPC	STRIKE-001 / KTX-2001 (NSD2 inhibitor) First clinical trial of NSD2 inhibitor. NSD2 drives aggressive/neuroendocrine disease and helps tumors evade the immune system. Combined with Darolutamide.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	UPDATE: INKmune CaRe trial Immunotherapy priming NK cells. Effective activation seen in patients with low baseline NK activity. Some lesions disappeared completely during therapy.	1/2	n.a.	n.a.	n.a.
NCT07088588	mCRPC (HRR+)	SYN608 / PARG inhibitor Targets the PARG enzyme in tumors with HRR deficiencies (BRCA, ATM). Lab tests show efficacy even in tumors resistant to standard PARP inhibitors.	1	n.a.	n.a.	n.a.
NCT07090369	mCRPC	LumOnate / Triple Combo Synergistic combo: 177Lu-PSMA (radiation) + Olaparib (DNA repair block) + Pembrolizumab (immune activation). Evaluates safety of triple mechanism.	1b	n.a.	n.a.	66*
NCT05875168	mCRPC	DS-3939a / TA-MUC1 ADC Targets tumor-associated MUC1, found in 90% of cases with lymph node spread. Uses DXd technology to deliver Topoisomerase I payload.	1/2	n.a.	n.a.	n.a.
NCT07189871	mCRPC	Betabart (RV-01) / B7-H3 Radioligand First-in-human trial for B7-H3 targeted radioligand. Uses Lutetium-177 but clears via the liver instead of kidneys, potentially reducing renal toxicity.	1	n.a.	n.a.	n.a.
NCT07080242	NEPC	BL-M14D1 / TROP2 ADC ADC targeting TROP2 for neuroendocrine prostate cancer. Uses stable linker to release topoisomerase I inhibitor only inside the cancerous cell.	1	n.a.	n.a.	n.a.
n.a.	mHSPC / mCRPC	Low-Dose Abiraterone (500mg) + Food Singapore hospital trial showing 500mg with meal achieves >80% enzyme occupancy. 78% achieved PSA50; 91.1% reduction seen in mCRPC cohort.	1	n.a.	n.a.	78*
n.a.	mCRPC (AR altered)	PC-BETS Substudy C / Darolutamide Biomarker trial using ctDNA. Enriched benefit seen in patients with AR copy number >10, though overall results were modest for ARPI-to-ARPI switch.	2	n.a.	n.a.	n.a.
n.a.	mCRPC	PSMAfore / 177Lu-PSMA-617 (Pluvicto) Phase 3 trial in taxane-naive patients. Showed 59% lower risk of progression. PSA50 response rate reached 50.7% vs 14.9% for ARPI switch.	3	12.0*	24.48	50.7
n.a.	mHSPC	UPDATE: PSMAddition / Pluvicto Announced that Pluvicto plus standard care significantly extended rPFS in the hormone-sensitive setting. Full data expected in late 2025.	3	n.a.	n.a.	n.a.
n.a.	mCRPC	Pluvicto + TRE-515 / dCK inhibitor Combination therapy pairing Pluvicto with a first-in-class dCK inhibitor. Aims to disrupt DNA precursor supply to make cells more vulnerable to radiation.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	Masitinib + Docetaxel Phase 3 trial for patients with low alkaline phosphatase (ALP ≤ 250). Previous data showed 47% reduced risk of progression in ALP ≤ 100 subgroup.	3	n.a.	n.a.	n.a.
NCT06190899	mCRPC	CELC-G-201 / Gedatolisib + Darolutamide Targets PI3K/AKT/mTOR and AR pathways. Early results show 6-month rPFS rate of 66% with no treatment discontinuations due to side effects.	1/2	6.6*	n.a.	n.a.
NCT07028853	mCSPC	MEVPRO-3 / Mevrometostat + Enzalutamide Phase 3 trial evaluating EZH2 inhibitor in mCSPC. Previous data in mCRPC showed rPFS of 14.3 months vs 6.2 months for enzalutamide alone.	3	14.3*	n.a.	34.1*
NCT07006727	NEPC	225Ac-ETN029 / DLL3 Alpha Therapy Radiopharmaceutical using Actinium-225 to target DLL3, expressed in 77% of neuroendocrine prostate cancer (NEPC) cases.	1	n.a.	n.a.	n.a.
n.a.	mCRPC (EBV+)	WGc-043 / EBV mRNA Vaccine Targets tumors linked to Epstein-Barr virus. Explores the connection between EBV and advanced disease stages in subsets of PCa patients.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	Cu-61 NuriPro / PSMA Imaging Next-gen PET imaging agent. Detected more lesions in 50% of patients compared to F-18 tracers. Therapeutic Cu-67 version planned for 2026.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	225Ac-LNC1011 / Alpha Emitter Targeted alpha therapy showing 50% ORR (RECIST) and 75% ORR (PET-based). One patient achieved a PSA drop from 7.8 to 0.18 ng/mL.	1	n.a.	n.a.	100*
n.a.	mCRPC	ART-101 / PSMA small molecule Theranostic small molecule with higher tumor retention and lower salivary uptake than approved agents. Compatible with Ac-225 and Lu-177.	1	n.a.	n.a.	n.a.
NCT06907043	mCRPC	EIK1004 (IMP1707) / PARP1 inhibitor Selective PARP1 inhibitor designed to cross the blood-brain barrier. Aims to treat CNS metastases while sparing PARP2 to reduce side effects.	1/2	n.a.	n.a.	n.a.
NCT06943521	mCRPC / NEPC	MT-4561 / BRD4 Degrader Destroys BRD4 protein via ubiquitin-proteasomal degradation. Targets the BRD4-KDM5C-PTEN axis which drives CRPC evolution and invasion.	1/2	n.a.	n.a.	n.a.
NCT07024277	NEPC	ZG006 / DLL3 Trispecific Engager Trispecific T-cell engager targeting two DLL3 sites. Preclinical studies showed complete disappearance of tumors in some models.	2	n.a.	n.a.	n.a.
NCT06925737	mCRPC	IDeate-Prostate01 / Ifinatamab Deruxtecan Phase 3 trial comparing B7-H3 ADC vs Docetaxel. Early data showed 25% response rate in heavily pretreated mCRPC patients.	3	n.a.	n.a.	n.a.
NCT07007910	mCRPC	HSK46575 / CYP11A1 inhibitor Small molecule targeting an earlier step in hormone production than abiraterone. Designed to stay longer in the body with once-daily dosing.	1	n.a.	n.a.	n.a.
NCT07002320	mCRPC	ASpiRE / SX-682 + Apalutamide Targets CXCR1/2 to dismantle the ‘immunosuppressive cloak’ (MDSCs) that shields PCa from the immune system. Combined with AR inhibitors.	1/2	n.a.	n.a.	n.a.
NCT06999187	mCRPC	DR-0202 / CLEC7A Bispecific Antibody Leverages myeloid cells to engulf tumor cells. Priming mechanism teaches T-cells to recognize unique tumor markers for long-lasting immunity.	1a/1b	n.a.	n.a.	n.a.
NCT06895811	mCRPC	BRL-302 / Switchable CAR-T UCAR technology with a ‘light switch’ control. Allows doctors to turn off T-cell activity within hours if side effects (CRS) become too strong.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	PMR-116 / MYC inhibitor Disrupts the rRNA synthesis machinery that the MYC oncogene depends on. Preclinical data: 85% reduction in MYC-driven prostate cancer lesions.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	OncoACP3 / ACP3 Targeted Radioligand Targets Acid Phosphatase 3, highly specific to PCa. Compatible with Actinium-225 for high localized tumor kill with reduced side effects.	1	n.a.	n.a.	n.a.
NCT06982222	mCRPC (Bone Metastases)	Sn-117m-DTPA / Tin Radiopharmaceutical Theranostic agent for painful bone metastases. Emits low-energy electrons to treat the bone while sparing marrow toxicity. 30% achieved complete pain resolution.	1/2	n.a.	n.a.	n.a.
NCT05932862	mCRPC (BRCA+)	XL309 / USP1 inhibitor Targets DNA repair enzyme USP1. Designed to overcome or synergize with standard PARP inhibitor therapy in BRCA-mutated tumors.	1	n.a.	n.a.	n.a.
NCT06801236	mCRPC	UPDATE: ACE-232 / CYP11A1 inhibitor Novel oral inhibitor showing potential superiority to earlier CYP11A1 drugs. Aims to suppress androgen production even in treatment-resistant cases.	1	n.a.	n.a.	n.a.
n.a.	mCSPC (HRR+)	AMPLITUDE Update / Niraparib + Abiraterone Combination therapy reduced progression risk by 37% in all HRR mutated and 48% specifically in BRCA1/2 mutated hormone-sensitive patients.	3	29.5*	n.a.	n.a.
n.a.	Localized (Intermediate/High Risk)	CAN-2409 / Biological Immunotherapy Viral therapy delivering HSV-tk gene to tumors. 30% reduction in recurrence risk when combined with radiation and valacyclovir.	3	n.a.	n.a.	67.1
NCT05413421	mCRPC	ORIC-944 / PRC2 inhibitor Allosteric inhibitor combined with ARPIs. Deep responses seen: 59% PSA50 and 24% PSA90 response rates in patients who failed prior AR therapies.	1b	n.a.	n.a.	59
NCT06991556	mHSPC	JSB462 (Luxdegalutamide) + Abiraterone PROTAC degrader targeting wild-type and mutated AR. Aims to physically eliminate the receptor to prevent resistance found in 24% of mCRPC cases.	2	n.a.	n.a.	43*
NCT04939610	mCRPC	LuMIERE / 177Lu-FAP-2286 Radioligand targeting CAFs in the tumor microenvironment. Effectively treats bone metastases (3.0 Gy/GBq) with minimal kidney or marrow exposure.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC (HRR+)	TALAPRO-2 / Talazoparib + Enzalutamide Subgroup analysis showed most pronounced benefit in BRCA2 (rPFS 30.7m vs 12.3m). Significant response also seen in CDK12 and ATM subgroups.	3	30.7*	45.1*	69.4
n.a.	mCRPC	177Lu-PSMA-I&T (Swiss registry) Prospective registry of 333 patients. Confirmed safety and efficacy comparable to Pluvicto. 17% achieved PSA90 response.	2	6.5*	13	41
NCT02446405	mHSPC	ENZAMET (8-Year Follow-up) / Enzalutamide Landmark trial showing enzalutamide extended median OS by 25 months vs older NSAAs. Median OS was 95 months in the treatment group.	3	n.a.	95	n.a.
NCT04898634	mCRPC	JNJ-78278343 (Pasritamig) / KLK2 T-cell engager Targets KLK2 (specific to PCa tissue). PSA50 response rate of 42.4% in heavily pretreated patients. Durable responses up to 11.2 months.	1	6.77	n.a.	42.4
NCT06383052	mCRPC	177Lu-NYM032 / PSMA Radioligand Novel Chinese radionuclide conjugate engineered to maximize radiation to tumor while sparing healthy tissue. 67% PSA50 response rate.	1	n.a.	n.a.	67
NCT05682443	mCRPC	PRESERVE-006 / 177Lu + Gotistobart (BNT316) Pluvicto combined with innovative anti-CTLA-4. Depleting Tregs in the tumor microenvironment amplified Pluvicto response (66.7% vs 16.7%).	1/2	n.a.	n.a.	66.7*
n.a.	mCRPC	VIOLET / 161Tb-PSMA-I&T Uses Terbium-161 (beta + Auger emissions). Auger electrons enhanced destruction of micrometastases. 70% PSA50 response achieved.	1/2	11.1	n.a.	70
NCT06139575	mCRPC	JH020002-01C / 177Lu-JH020002 Heavily pretreated cohort (including Ra-223 and PARPi). 63.6% PSA50 response rate at higher doses, with one partial radiographic response.	1/2	n.a.	n.a.	63.6
n.a.	mCRPC	MHB088C / B7-H3 ADC Uses ‘SuperTopoi’ payload, 5-10 times more potent than standard ADC toxins. 6-month rPFS was 87% in heavily pretreated mCRPC.	1/2	n.a.	n.a.	n.a.
NCT03460977	mCRPC	UPDATE: Mevrometostat (EZH2 inhibitor) Phase 2 expansion for abiraterone-experienced patients. Median rPFS significantly improved to 14.3 months vs 6.2 for enzalutamide alone.	2	14.3	n.a.	34.1
NCT03317392	mCRPC	COMRADE / Olaparib + Radium-223 Combination for bone metastases. Improved rPFS regardless of HRR status. Significantly delayed time to next treatment (12.0m vs 7.7m).	2	8.6*	n.a.	n.a.
n.a.	mCRPC	TALAPRO-2 / Talazoparib + Enzalutamide Final OS analysis for all-comers. Median OS reached 45.8 months vs 37.0 months for enzalutamide alone. Benefit was strongest in HRR-mutated patients (nearly 50% death risk reduction).	3	33.1	45.8*	n.a.
n.a.	mCRPC	PT-112 / Pyrophosphate Platinum Novel platinum agent with osteotropism for bone metastases. Induces immunogenic cell death. 17% of patients in Phase 1 achieved rPFS ≥ 6 months.	3	6*	n.a.	n.a.
n.a.	mCRPC	KEYNOTE-641 / Pembrolizumab + Enzalutamide Trial stopped for futility. Addition of pembrolizumab did not improve OS (24.7m vs 27.3m) or rPFS and increased toxicity in chemo-naive patients.	3	10.4	24.7	n.a.
n.a.	mCRPC	UPDATE: JANX007 / PSMA-TRACTr Tumor-activated T-cell engager. Phase 1a data showed 7.9 months median rPFS at higher doses with 78% 6-month rPFS rate. Expanding to taxane-naive and ARPi resistant cohorts.	1b	7.9*	n.a.	100
n.a.	mCRPC	NTS071 / p53 Y220C Mutation Target AI-designed small molecule targeting the p53 Y220C mutation. Stabilizes mutant p53 to restore tumor suppressor function. Tumor-agnostic approach including PCa.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	CAPItello-280 / Capivasertib + Docetaxel Trial discontinued. Regimen unlikely to meet primary endpoints of rPFS and OS in the overall population of patients progressed on ADT.	3	n.a.	n.a.	n.a.
NCT05415098	mCRPC	APG-5918 / EED inhibitor Inhibitor of EED (PRC2 component). Synergistic with enzalutamide in preclinical models. Induces G0/G1 cell cycle arrest even in AR-independent tumors.	1	n.a.	n.a.	n.a.
NCT06224387	mCRPC	CTS2190 / PRMT1 inhibitor Orally available inhibitor of PRMT1. Causes degradation of AR, including resistant AR-V7 variants. Outperformed standard treatments in preclinical CRPC models.	1	n.a.	n.a.	n.a.
NCT06666270	mCRPC (HRR+)	SYN818 / DNA Polymerase Theta (POLQ) inhibitor Exploits vulnerabilities in tumors with BRCA1/2 or ATM mutations. Intended to be combined with PARP inhibitors to intensify DNA damage in HRR-deficient cells.	1	n.a.	n.a.	n.a.
NCT05873686	mCRPC	NXP900 / SFK inhibitor Locks SRC and YES1 kinases in an inactive form. Preclinical data suggests it can reverse acquired resistance in mCRPC models when combined with enzalutamide.	1	n.a.	n.a.	n.a.
NCT06318273	mCRPC	ABBV-969 / Bispecific ADC (STEAP1 + PSMA) Dual-targeting ADC engaging both STEAP1 and PSMA. Aimed at improving tumor cell coverage in heterogeneous tumors using a topoisomerase-1 inhibitor payload.	1	n.a.	n.a.	n.a.
NCT05800665	mCRPC	GDC-2992 / AR Degrader + Antagonist Dual-action molecule: degrades AR protein via cereblon (CRBN) and acts as a competitive antagonist. Effective against resistant AR mutants in preclinical models.	1	n.a.	n.a.	n.a.
n.a.	mCRPC (HRR+)	IMP1734 (EIK1003) / PARP1 inhibitor Next-gen PARP1-selective inhibitor. Designed to spare PARP2 to reduce common side effects like anemia and low white blood cell counts seen with older PARP inhibitors.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC	GSK5764227 (HS-20093) / B7-H3 ADC Antibody-drug conjugate targeting B7-H3, prevalent in aggressive PCa. Tested alone and with cisplatin or pembrolizumab. Already showed promise in Asian studies.	1	n.a.	n.a.	n.a.
n.a.	nmHSPC	Grape Seed Extract (GSE) / Phytochemical Phase 2 trial for biochemical recurrence. GSE significantly slowed PSA doubling time (PSADT) from 5.7 to 6.8 months. 78% of men saw some benefit.	2	n.a.	n.a.	37*
n.a.	mCRPC / NEPC	BA1106 / anti-CD25 antibody Depletes regulatory T cells (Tregs) to shift the balance toward anti-tumor immunity. Does not block IL-2 signaling. Shown durable control in neuroendocrine models.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	Q702 / Axl, Mer, CSF1R triple inhibitor Blocks three proteins that drive resistance and shield tumors from the immune system. Demonstrated target engagement and stable disease in heavily pretreated patients.	1	n.a.	n.a.	n.a.
NCT03972657	mCRPC	Nezastomig (REGN5678) + Cemiplimab Combination of bispecific antibody and PD-1 booster. 25% achieved PSA50 at higher doses. Survival was 17.3m vs 10.3m for lower doses, but safety is a concern (14% severe reactions).	1/2	5.0*	17.3*	25
n.a.	nmHSPC	TGW101 / TAG-72 ADC ADC targeting TAG-72 using ‘Click-to-Release’ technology. Primarily present in early/localized PCa (88%) but expression drops in late metastases.	1	n.a.	n.a.	n.a.
NCT06657222	mCRPC	Tubulis / 5T4-targeted ADC Targets 5T4 oncofoetal glycoprotein. High expression in mCRPC. Uses a stable cleavable linker and Exatecan payload to improve targeting precision.	1	n.a.	n.a.	n.a.
NCT06926075	mCRPC	ADVICE / Kesonotide Dual anti-inflammatory and chemo drug targeting Vimentin in both tumor cells and the supporting microenvironment (TME). Blocks EMT and invasiveness.	1b/2a	n.a.	n.a.	n.a.
NCT06573294	mCRPC	GEN1057 / DuoBody-FAPαxDR4 Bispecific antibody that triggers apoptosis (DR4) only when FAP-alpha is nearby. High localized precision avoids liver damage seen with earlier DR4 drugs.	1	n.a.	n.a.	n.a.
NCT06863272	mCRPC	MK-2400 (Ifinatamab Deruxtecan) / TROP2 ADC ADC targeting TROP2. Interim data in NSCLC showed 52.4% ORR. Evaluating if similar strong responses occur in TROP2-expressing prostate cancers.	1	n.a.	n.a.	n.a.
NCT06922318	mCRPC	COSMYC / ZEN-3694 + BAT Combined suppression of MYC. Pairs BET inhibitor (ZEN-3694) with Bipolar Androgen Therapy (BAT) to sensitize tumors to subsequent enzalutamide treatment.	2	n.a.	n.a.	n.a.
NCT06909825	mCRPC	FPI-2265 (225Ac-PSMA) + Olaparib Combines Targeted Alpha Therapy with PARP inhibitor. Enrolment does not require HRR mutation. Aims to enhance DNA damage via Alpha-radiation and repair-blockade.	2	n.a.	n.a.	n.a.
NCT06889493	mCRPC / NEPC	SVV-001 + Checkpoint inhibitors Seneca Valley Virus (Oncolytic virus) combined with Nivolumab/Ipilimumab. Virus selectively kills tumor cells and releases antigens to turn ‘cold’ neuroendocrine tumors ‘hot’.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	FC705 / PSMA Radioligand (Korea) Achieved 60% ORR in Phase 2 for bone/soft tissue. PSA50 response rate of 73.3% significantly outperformed VISION benchmarks (46%).	2	n.a.	n.a.	73.3
n.a.	n.a.	PGV001 / Personalized Cancer Vaccine Multi-peptide neoantigen vaccine. At 5-year follow-up, 3 of 13 patients remained tumor-free. Stimulates immune response to prevent recurrence after surgery/chemo.	1	n.a.	60*	n.a.
NCT06910657	mCRPC	IDOV-Immune / Oncolytic Virus Based on Vaccinia virus. Engineered to selectively infect and rupture cancer cells (oncolysis), acting as a personalized vaccine inside the body.	1	n.a.	n.a.	n.a.
NCT06260774	mCRPC	TTX-MC138 / RNA Therapeutic Inhibits miR-10b, a master regulator of metastasis. Delivered via nanoparticle platform. Achieved persistent regression of metastases in preclinical models.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	UPDATE: ENV105 / Carutoximab Safety lead-in completed for combo with apalutamide. Aims to reverse resistance to ARSIs by targeting CD105 in the tumor microenvironment.	2	13*	n.a.	n.a.
n.a.	mCRPC	FOR46 (FG-3246) / CD46 ADC Targets CD46 protein on PCa cells. PSA50 response rate of 36% and ORR 20%. Median rPFS of 8.7 months in patients who exhausted prior ARPIs.	1	8.7	n.a.	36
n.a.	mCRPC (Bone metastases)	SKB107 / TBM-001 (RDC) Chinese Radionuclide-Drug Conjugate (RDC). Targets and destroys bone lesions directly. Designed to manage pain and fractures in 80% of metastatic patients.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	Pocenbrodib / p300/CBP inhibitor First AI-designed drug to enter mCRPC trials. Targets p300/CBP epigenetic regulators. Developed from initiation to human dosing in under 30 months.	1/2	n.a.	n.a.	n.a.
n.a.	mHSPC	LIBERTAS / Apalutamide + Intermittent ADT Investigates de-escalation by using apalutamide alone if PSA < 0.2 after 6 months. High initial success: 71% achieved undetectable PSA.	3	n.a.	n.a.	71*
NCT06879041	mCRPC	AZD2284 + AZD2287 + AZD2275 Actinium-225 therapy phase. Explores a strategy utilizing biomarkers PSMA and STEAP2 simultaneously to improve biodistribution and therapeutic effect.	1	n.a.	n.a.	n.a.
NCT05413850	mCRPC	177Lu rhPSMA-10.1 / rhPSMA Radioligand Next-gen radiohybrid PSMA. Demonstrated 100% PSA reduction in pilot cases. Tumor-to-healthy tissue ratio is superior to traditional PSMA ligands.	1/2	24*	n.a.	100*
n.a.	mCRPC	UPDATE: FutureChem FC705 / PSMA radioligand Phase 3 trial in Korea. Uses an albumin-binding ligand to extend blood circulation. 60% achieved PSA50 in Phase 2 despite heavy prior treatment.	3	n.a.	n.a.	60*
NCT06541639	mCRPC	EVM16 CX01 / Personalized mRNA Vaccine AI-based neoantigen prediction algorithm EVER-NEO-1. Encodes patient-specific mutations. Combined with Tislelizumab (anti-PD-1) to boost effectiveness.	1	n.a.	n.a.	n.a.
NCT06782555	mCRPC	IMGS-101 (Evofosfamide) + Checkpoint inhibitors Hypoxia-modifying agent. Targets low oxygen tumor zones which usually restrict T-cell infiltration. Aims to restore checkpoint inhibitor efficacy in mCRPC.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC	UPDATE: SECuRE / 67Cu-SAR-bisPSMA Copper-67 based radiopharmaceutical. Data shows 92% response rate (PSA >35% reduction) in pre-chemotherapy participants. 45% achieved PSA50 response.	2	n.a.	n.a.	45
NCT06855277	mCRPC	AAA817 / 225Ac-PSMA-617 + ARPI Phase 3 trial evaluating Targeted Alpha Therapy (Ac-225) in combination with ARPI for chemo-naive patients. Targets PSMA-positive tumor cells with high localized energy.	3	9.1*	12.5*	66*
NCT06842498	mCRPC	FG-3246 (FOR46) / CD46 ADC Antibody-drug conjugate targeting CD46. Phase 1b results with enzalutamide showed a median rPFS of 10.2 months in biomarker-unselected patients.	2	10.2	n.a.	n.a.
NCT06229366	mHSPC / mCRPC	ACCEL / Actinium-225-PSMA-62 Investigates Ac-225 alpha therapy in oligometastatic hormone-sensitive (OmHSPC) and mCRPC. PSMA-62 ligand is engineered for better cellular internalization.	1/2	n.a.	n.a.	n.a.
NCT04876651	mCRPC	ProstACT Global / TLX591 Uses the rosopatamab antibody to carry Lutetium-177. Binds to PSMA with higher affinity than peptides, allowing for lower radiation doses and fewer side effects.	3	n.a.	n.a.	n.a.
NCT06840535	mCRPC	OncoACP3 / ACP3 Targeted Radiotracer Targets Acid Phosphatase 3 (ACP3), which is more specific to PCa than PSMA. Aims for clearer imaging and more potent localized radiotherapy when paired with Ac-225.	1	n.a.	n.a.	n.a.
NCT05534646	mCRPC	ENV105 (Carutoximab) + Apalutamide Targets CD105 (endoglin) to disrupt the BMP signaling pathway. Designed to restore sensitivity to AR inhibitors in treatment-resistant tumors.	2	n.a.	n.a.	n.a.
NCT04868604	mCRPC	UPDATE: SECuRE / 67Cu-SAR-bisPSMA Copper-67 radioligand. Fast Track granted after one patient achieved complete response (undetectable PSA for 13 months) following two 8 GBq doses.	1/2	n.a.	n.a.	45
n.a.	mCRPC (Visceral/Liver)	COSMIC-021 / Cabozantinib + Atezolizumab Combination for patients with visceral metastases. In the liver subgroup, median survival reached 14.7 months vs 5.0 months for cabozantinib alone.	1	n.a.	14.7*	n.a.
n.a.	mHSPC	STAMPEDE / Transdermal Estradiol Comparison of estrogen patches vs LHRHa injections. Shows identical PSA response rates with better bone health and lower cardiovascular risk.	2	n.a.	n.a.	n.a.
n.a.	mCRPC (HRR+)	Final OS TALAPRO-2 / Talazoparib + Enzalutamide Final results for HRR-deficient patients. Median OS of 45.1 months. BRCA1/2 group median OS not reached vs 28.5m in placebo.	3	30.7*	45.1*	n.a.
n.a.	mCRPC	CBP-1018 / Bi-ligand-drug conjugate Dual-targeting drug conjugate. Showed 88% disease control rate and 66% 7-month rPFS rate in heavily pretreated patients who failed taxanes and ARPIs.	1/2	n.a.	n.a.	n.a.
n.a.	Localized (Slow progress)	Gut-Prostate Axis / Phytochemicals + Probiotics Double-blind trial using supplement with ginger, green tea, etc. Adding probiotics reversed PSA growth from 21.7% rise to 20% decrease.	n.a.	n.a.	n.a.	n.a.
n.a.	mCRPC	UPDATE: Mevrometostat (EZH2 inhibitor) Phase 1 update showing 49% reduction in death risk when combined with hormone therapy in patients previously treated with taxanes.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	MaaT Pharma / Microbiome Therapy Restoring microbial diversity to enhance immunotherapy. transplantation of microbiota alongside anti-PD1 shown to improve response rates.	n.a.	n.a.	n.a.	n.a.
n.a.	mCRPC / NEPC	BR111 / ROR1-targeted ADC ADC targeting ROR1, expressed in castration-resistant small cell and neuroendocrine prostate cancers. Dual-epitope mechanism to reduce escape mutations.	n.a.	n.a.	n.a.	n.a.
n.a.	mCRPC	177Lu-DGUL + Keytruda First Korean trial combining radioligand and immune checkpoint inhibitor. PSMA-targeting radiation primes the tumor for anti-PD1 therapy.	1	n.a.	n.a.	n.a.
n.a.	mCRPC (PCPro+)	Opaganib + Darolutamide Targets sphingosine kinase-2 (SPHK2) to overcome resistance to AR inhibitors. Uses a specific lipid biomarker test (PCPro) for patient selection.	2	n.a.	n.a.	n.a.
NCT06800313	mCRPC	HLD-0915 / RIPTAC Regulated Induced Proximity Targeting Chimera. Induces proximity between AR and transcriptional regulators to cause selective cancer cell death.	1	n.a.	n.a.	59
NCT06801236	mCRPC	ACE-232 / CYP11A1 inhibitor Selective oral inhibitor designed to overcome resistance caused by AR-LBD mutations or amplification. Suppresses androgen production more potently than abiraterone.	1	n.a.	n.a.	n.a.
NCT06265727	mCRPC	CRB-701 (SYS6002) / Nectin-4 ADC ADC targeting Nectin-4, overexpressed in many PCa cases. Preliminary data across solid tumors showed ORR of 40% at doses ≥ 2.7 mg/kg.	1/2	n.a.	n.a.	n.a.
NCT06465069	mCRPC	LY4052031 & LY4101174 / Nectin-4 ADCs Novel ADCs combining human monoclonal antibody with topoisomerase I inhibitor payload. Designed to target both high and low Nectin-4 expressing tumors.	1a/1b	n.a.	n.a.	n.a.
NCT06056791	mCRPC	CaRe Trial / INKmune Terapia immunitaria che ‘risveglia’ le cellule NK dormienti del paziente. Espansa per includere i veterani americani. Somministrata via infusione ambulatoriale.	1/2	n.a.	n.a.	n.a.
NCT06785636	mCRPC	Pocenbrodib / p300/CBP inhibitor Inibitore dei regolatori epigenetici p300/CBP scoperto tramite IA. Testato come monoterapia e in combinazione con ARPI, Olaparib o Pluvicto.	1	n.a.	n.a.	n.a.
NCT06782555	mCRPC	Evofosfamide + Checkpoint Inhibitors Farmaco attivato dall’ipossia tumorale. Mira a distruggere le zone prive di ossigeno che proteggono il tumore dal sistema immunitario.	1/2	n.a.	n.a.	n.a.
NCT06780670	mCRPC	AAA817 / 225Ac-PSMA-617 Studio registrativo per terapia alfa con Attinio-225 in pazienti già trattati con Lutezio-177 (Pluvicto) e taxani.	2/3	n.a.	n.a.	66*
NCT06781983	mCRPC	IPH4502 / Nectin-4 ADC ADC che lega anticorpo anti-Nectin-4 al payload Exatecan. Mirato a tumori con espressione variabile di Nectin-4, inclusa la prostata.	1	n.a.	n.a.	n.a.
NCT05369000	mCRPC	LAVA-1207 / T-cell engager Sviluppo interrotto per mancato raggiungimento dei benchmark interni di efficacia, nonostante segnali positivi di riduzione del PSA in alcuni pazienti.	1	n.a.	n.a.	n.a.
NCT06778863	mCRPC (p53 mutant)	CLSP-1025 / p53 R175H targeted engager T-cell engager ultra-preciso che bersaglia specificamente la forma mutata della proteina p53, presente in molti tumori solidi aggressivi.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	VIR-5500 / PSMA T-cell engager Anticorpo bispecifico con tecnologia di mascheramento per attivarsi solo sul tumore. 58% dei pazienti ha ottenuto risposta PSA50.	1	n.a.	n.a.	58
n.a.	mCRPC	ORIC-944 / PRC2 inhibitor Inibitore allosterico del complesso PRC2 combinato con ARPI. Risposte PSA90 durature (fino a 38 settimane) osservate nella fase 1b.	1b	n.a.	n.a.	50*
n.a.	Localized (High risk)	CAN-2409 / Oncolytic Immunotherapy Adenovirus iniettato nel tumore che attiva il farmaco Valtrex. Riduzione del 30% del rischio di ricorrenza nel tumore localizzato ad alto rischio.	3	n.a.	n.a.	n.a.
NCT06764485	mCRPC	BMS-986365 / AR Degrader + Antagonist Doppio meccanismo: degrada il recettore androgeno e lo blocca. In fase 1, il 70% dei pazienti ha avuto un calo del PSA del 30%.	3	6.3*	n.a.	n.a.
n.a.	mCRPC	PNKP inhibitor / DNA repair target Mira a inibire l’enzima PNKP per sensibilizzare le cellule cancerose alla radioterapia o alla chemio impedendo la riparazione del DNA.	1	n.a.	n.a.	n.a.
NCT06710379	mCRPC	ADRX-0405 / STEAP1 ADC ADC con rapporto farmaco-anticorpo (DAR) di 8. Colpisce STEAP1, altamente espresso nella prostata e quasi assente nei tessuti sani.	1	n.a.	n.a.	n.a.
NCT05719558	mCRPC	ASP1002 / Claudin 4 Bispecific Lega Claudin 4 sul tumore e CD137 sulle cellule T. Attiva il sistema immunitario contro tumori che esprimono Claudin 4 (frequente nella prostata).	1	n.a.	n.a.	n.a.
NCT06734130	mCSPC	Adaptive ADT + Docetaxel Modello di terapia ormonale intermittente guidato da algoritmi individuali sulla base della risposta PSA per ridurre la tossicità a lungo termine.	2	n.a.	n.a.	n.a.
n.a.	nmCRPC	WOMBAT / BAT + Darolutamide Studio australiano su Bipolar Androgen Therapy in pazienti M0 con PSA in risalita durante darolutamide.	2	n.a.	n.a.	n.a.
NCT06705686	mCRPC	PHAROS / (R)-9bMS (ACK1 inhibitor) Inibitore della proteina ACK1. Potrebbe ridurre i livelli di AR-V7, rendendo il cancro di nuovo sensibile alle ormonoterapie standard.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	KPG-121 / Cereblon modulator Modulatore di Cereblon con effetto anti-angiogenico. Efficacia precoce: 37,5% risposta parziale e 75% tasso di controllo della malattia.	1	n.a.	n.a.	37.5
NCT05652686	NEPC	SKYBRIDGE / PT217 (DLL3 x CD47) First-in-class bispecific antibody targeting DLL3 and CD47. Specifically designed for neuroendocrine prostate cancer (NEPC) and small cell lung cancer.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC (Low PSMA)	67Cu-SAR-bisFAP / 67Cu-SAR-Bombesin Radiopharmaceuticals for patients with low PSMA expression. Targets Gastrin-Releasing Peptide receptor (GRPr) or Fibroblast Activation Protein (FAP) in the microenvironment.	1	n.a.	n.a.	n.a.
n.a.	n.a.	Ketogenic Diet / Beta-hydroxybutyrate (BHB) Investigates how T-cells favor BHB as energy. A ketogenic diet or BHB supplements may supercharge CAR-T therapy by improving immune cell metabolism.	1	n.a.	n.a.	n.a.
NCT06095089	mCRPC	JNJ-87189401 + JNJ-78278343 Dual bispecific antibody approach targeting PSMA and KLK2. JNJ-87189401 provides CD28 costimulation while JNJ-78278343 activates CD3 T-cells.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	UPDATE: Xaluritamig (AMG 509) / STEAP1 T-cell engager Phase 1/2 update: 36-60% PSA50 response rate. Median overall survival reached 17.7 months, comparable to Pluvicto, but targeting STEAP1 instead of PSMA.	1/2	8.3*	17.7	60*
NCT04969835	mCRPC (FAP+)	AVA6000 / FAP-activated Doxorubicin Peptide Drug Conjugate (PDC) that releases chemotherapy only when cleaved by FAP enzymes in the tumor. Dramatically reduces systemic toxicity of doxorubicin.	1	n.a.	n.a.	n.a.
NCT06582017	mCRPC	QXL138AM / CD138-targeted Mic Masked immuno-cytokine targeting CD138. Preclinical models showed 69% tumor growth inhibition in PCa. Mask is removed only in the tumor microenvironment.	1	n.a.	n.a.	n.a.
NCT06609005	mCRPC	INV-9956 / CYP11A1 inhibitor Inhibits hormone biosynthesis at the first step. Potent against AR L702H mutations. Superior tumor inhibition vs competitors in preclinical VCaP models.	1	n.a.	n.a.	n.a.
n.a.	mCRPC / nmHSPC	Copper-61 NODAGA-PSMA / Precision Imaging Phase 1 trial for a new isotope with a 3.3-hour half-life. Aims to detect PSMA-positive lesions with better accessibility and geographic distribution than 68Ga.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	VVD-130850 / STAT3 inhibitor Oral allosteric inhibitor of STAT3. Blocks hyperactivation of STAT3 which drives metastasis and immune evasion in advanced prostate cancer.	1	n.a.	n.a.	n.a.
NCT04221542	mCRPC	Xaluritamig (AMG 509) Phase 3 / STEAP1 T-cell engager Randomized Phase 3 comparing xaluritamig vs cabazitaxel or AR switch. For patients previously treated with taxane chemotherapy.	3	n.a.	n.a.	n.a.
n.a.	nmHSPC (Active Surveillance)	High Omega-3 Diet + Fish Oil / Ki-67 marker Trial in 100 men on active surveillance. Intervention group saw 15% reduction in Ki-67 (proliferation marker) compared to 24% increase in the control group.	n.a.	n.a.	n.a.	n.a.
n.a.	mCRPC	STARt-001 / Invikafusp Alfa (STAR0602) Selectively activates specific T-cell subsets. 50% disease control rate in anti-PD-1 resistant patients. TMB-H subgroup showed 25% ORR.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC	AO-252 / TACC3 inhibitor Targets TACC3 protein involved in cancer cell proliferation. Preclinical studies support efficacy in prostate cancer by restraining primary cilium formation.	1	n.a.	n.a.	n.a.
NCT01436968	Localized (High risk)	PrTK03 / CAN-2409 + Radiotherapy Viral immunotherapy using HSV-tk. Phase 3 met primary endpoint with 14.5% improvement in Disease-Free Survival (DFS) in intermediate-to-high risk patients.	3	n.a.	n.a.	n.a.
n.a.	mCRPC	RaLu Trial / Ra-223 followed by Lu-177 Retrospective study showing Radium then Lutetium sequence is safe and feasible. Outcomes were similar regardless of time interval or prior taxane use.	Retrospective	n.a.	13.2*	n.a.
n.a.	mCRPC	LNCB74 / B7-H4 ADC ADC targeting B7-H4, which suppresses the immune system in aggressive PCa. Preclinical data shows significant advantages over existing B7-H4 agents.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	OP-3136 / KAT6 inhibitor Potent and selective small molecule inhibitor of KAT6 epigenetic regulators. Aims to disrupt oncogenic transcriptional programs.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	Talazoparib + Enzalutamide (Comparison) Matching-adjusted indirect comparison showing TALA+ENZA has superior rPFS compared to Olaparib/Abiraterone or Niraparib/Abiraterone.	n.a.	30.7*	n.a.	69.4*
n.a.	mCRPC	BNT324 (DB-1311) / B7-H3 ADC ADC targeting B7-H3. Phase 1 interim data showed 28% objective response rate and 7.2 months median rPFS in mCRPC.	1/2	7.2	n.a.	n.a.
n.a.	mHSPC	STAMPEDE / Metformin Metformin reduced metabolic side effects (weight gain) and lowered death risk by 10% in non-diabetic mHSPC patients.	3	n.a.	n.a.	n.a.
n.a.	mCRPC	JANX007 / PSMA-TRACTr Phase 1a results Tumor-activated T-cell engager. 100% of patients achieved PSA50 and 63% achieved PSA90. 50% ORR in RECIST evaluable patients.	1a	n.a.	n.a.	100
n.a.	mHSPC (PTEN-deficient)	CAPItello-281 / Truqap (Capivasertib) AKT inhibitor for PTEN-deficient mHSPC (25% of cases). Significantly improved rPFS when added to abiraterone and ADT.	3	n.a.	n.a.	n.a.
n.a.	mHSPC	ARANOTE / Darolutamide + ADT Randomized trial showing 46% reduction in radiographic progression or death compared to placebo + ADT. FDA accepted sNDA for this chemotherapy-free regimen.	3	n.a.	n.a.	62.6*
NCT06551324	mCRPC	MEVPRO-1 / Mevrometostat (EZH2 inhibitor) Phase 3 trial evaluating EZH2 inhibitor in men previously treated with abiraterone. EZH2 is a major driver of neuroendocrine differentiation.	3	n.a.	n.a.	n.a.
NCT04497844	mCSPC (HRR+)	AMPLITUDE / Niraparib + Abiraterone Evaluates combined PARP/AR inhibition in frontline hormone-sensitive setting for HRR-mutated patients. Primary endpoint is rPFS.	3	n.a.	n.a.	n.a.
NCT01436968	Localized (Intermediate-High risk)	CAN-2409 / Oncolytic virus immunotherapy Uses inactivated herpes virus to deliver toxic genes to cancer cells. Aiming for improved disease-free survival in localized cases.	3	n.a.	n.a.	n.a.
n.a.	mCRPC (Oligoprogressive)	MEDCARE / Progression-directed therapy (PDT) Radiotherapy targeted at new/progressing lesions while continuing current systemic therapy. Delayed next systemic treatment by median 17 months.	2	n.a.	n.a.	n.a.
NCT05204927	mCRPC	ECLIPSE / 177Lu-PSMA-I&T Targeted radiation therapy vs NHA switching. Significantly prolonged rPFS in PSMA-positive patients who failed one prior ARPI.	3	n.a.	n.a.	n.a.
n.a.	NEPC / Small Cell	Pembrolizumab + Chemotherapy (UCLA Study) Combines anti-PD1 with standard chemotherapy for aggressive small cell variants. Median survival reached 27 months (vs 9m historical).	1	n.a.	27	n.a.
n.a.	Localized / nmHSPC	White Button Mushroom (Agaricus bisporus) / MDSC target Integrative oncology study. Supplements reduced myeloid-derived suppressor cells (MDSCs) and increased anti-tumor T cells/NK cells in humans.	2	n.a.	n.a.	n.a.
n.a.	mCRPC	WB-EMS / Whole-body electromyostimulation Muscle stimulation training program. Serum collected from patients post-exercise significantly inhibited growth of PCa cells in vitro.	n.a.	n.a.	n.a.	n.a.
NCT02655822	mCRPC	Ciforadenant / Adenosine 2A Receptor block Targets adenosine-induced immunosuppression. 21% partial response (PSA >30%) when combined with atezolizumab.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	ProstACT GLOBAL / 177Lu-DOTA-rosopatamab (TLX591) Randomized Phase 3 for TLX591 radiopharmaceutical. Focuses on survival, QoL, and biodistribution in progressive mCRPC patients.	3	n.a.	n.a.	n.a.
NCT03724747	mCRPC	Thorium-227 (BAY2315497) / Targeted Alpha Therapy PSMA-TTC (Thorium conjugate). Effective in models resistant to standard enzalutamide. Synergistic with darolutamide in bone metastasis models.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	Benfo-Oxythiamine (B-OT) / Radiosensitizer Inhibits transketolase enzymes to sensitize tumor cells to 177Lu-PSMA. A case report showed substantial PSA decline and metastasis regression.	1	n.a.	n.a.	n.a.
n.a.	mCRPC	Blue Earth / 177Lu rhPSMA-10.1 Dosimetry findings revealed high tumor-to-organ radiation ratios. Phase 2 trial will test front-loaded radioactivity to extend treatment duration.	1/2	n.a.	n.a.	n.a.
n.a.	mCRPC	Masofaniten (EPI-7386) + Enzalutamide Phase 2 trial halted. Interim review showed no added benefit of masofaniten over enzalutamide alone in PSA90 response rates.	2	n.a.	n.a.	n.a.
n.a.	mCRPC	Camcevi / Leuprolide Mesylate (3-month) New depot formulation for ADT. 97.9% of patients in Phase 3 trial maintained testosterone suppression below 50 ng/dL.	3	n.a.	n.a.	n.a.
n.a.	mCRPC	ARROW / Iodine-131 PSMA + Enzalutamide Met primary endpoint for PSA response (62.9% vs 31.3%). Radiographic PFS showed no significant difference, but Iodine-131 remains a viable targeting option.	2	n.a.	n.a.	62.9
NCT05768139	mCRPC / nmHSPC	STX-478 / PI3Kα inhibitor Mutant-selective PI3Kα inhibitor. Reduced toxicity (no hyperglycemia) compared to older PI3K drugs. Demonstrated 21% ORR across solid tumors.	1	n.a.	n.a.	n.a.
n.a.	mHSPC	ARASENS Post-hoc / Darolutamide PSA response Post-hoc analysis showing 67% reached undetectable PSA. Sustained low PSA levels strongly correlated with longer OS and delayed transition to mCRPC.	3	n.a.	n.a.	67*
n.a.	mHSPC	ARASENS / Darolutamide + Docetaxel + ADT High-volume patients reached median rPFS of 43.7 months vs 19.1 months in control. Median OS was not reached in the darolutamide arm.	3	43.7*	n.a.	n.a.
n.a.	mCRPC	APEX-01 / ARX517 (PSMA ADC) ADC delivering microtubule inhibitor. 52% achieved PSA50 and 26% achieved PSA90 at higher dose levels. Highly favorable safety profile.	1/2	n.a.	n.a.	52*
n.a.	mHSPC	ARANOTE / Darolutamide + ADT Chemotherapy-free triplet alternative. Showed 46% reduction in radiographic progression risk and 62.6% reached undetectable PSA (<0.2 ng/mL).	3	n.a.	n.a.	62.6*